Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Genomics. 2010 May;95(5):312-4. doi: 10.1016/j.ygeno.2010.03.003. Epub 2010 Mar 10.

    Metastasizing patent claims on BRCA1.

    Source

    Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 27705, USA. kepler@duke.edu

    Abstract

    Many patents make claims on DNA sequences; some include claims on oligonucleotides related to the primary patented gene. We used bioinformatics to quantify the reach of one such claim from patent 4,747,282 on BRCA1. We find that human chromosome 1 (which does not contain BRCA1) contains over 300,000 oligonucleotides covered by this claim, and that 80% of cDNA and mRNA sequences contributed to GenBank before the patent application was filed also contain at least one claimed oligonucleotide. Any "isolated" DNA molecules that include such 15 bp nucleotide sequences would fall under the claim as granted by the US Patent and Trademark Office. Anyone making, using, selling, or importing such a molecule for any purpose within the United States would thus be infringing the claim. This claim and others like it turn out, on examination, to be surprisingly broad, and if enforced would have substantial implications for medical practice and scientific research.

    Copyright 2010 Elsevier Inc. All rights reserved.

    PMID:
    20226239
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2857658
    Free PMC Article

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk